SELLAS Life Sciences is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.

SELLAS’ lead product candidate, licensed from Memorial Sloan-Kettering Cancer Center (MSKCC), is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The WT1 antigen is one of the most widely expressed cancer antigens and ranked by the National Cancer Institute (NCI) as the top priority among cancer antigens for immunotherapy. Traditional approaches have not yet been proven to successfully address the WT1 protein, as WT1 is not druggable with small molecules and is intracellular and inaccessible to antibodies. SELLAS has been working with MSKCC since 2014, and MSKCC is also a current shareholder of SELLAS.

SELLAS plans to initiate a pivotal Phase 3 study in acute myeloid leukemia (AML) as well as malignant pleural mesothelioma (MPM). SELLAS is currently conducting Phase 1 and Phase 2 studies in multiple myeloma (MM) and ovarian cancer (combination with nivolumab (Opdivo®)) and will advance additional studies into the clinic. Phase 2 data in AML and MPM have shown positive safety and survival trends, with median overall survival (OS) in AML of 67.6 months vs. ~12-15 months for best standard treatment (in patients of all ages) and median OS in MPM of 24.8 months vs. 16.6 months in the control arm. Further recent data in MM has shown an 88% overall survival rate after 18 months in patients with high-risk cytogenetics following stem cell transplantation. The US FDA granted Orphan Designations and Fast Track Designations for SELLAS' WT1 therapy, galinpepimut-S, for AML and MPM and the EMA granted Orphan Designation for AML and MPM.

Galinpepimut-S has the potential to complement currently available therapies by destroying residual tumor cells of cancers in remission and providing ongoing immune surveillance to avoid or significantly delay tumor recurrence. Its use in this setting is aided by an attractive safety profile not yet been proven to be found in standard of care therapies.

SELLAS was founded in 2012 and its headquarters are in Hamilton, Bermuda, with an additional office in New York City.



Angelos M. Stergiou, MD, ScD h.c. , Chief Executive Officer & Vice Chairman of the Board

Dr. Angelos M. Stergiou, founder, CEO & Vice Chairman of the Board of SELLAS Life Sciences Group, Ltd. has held international positions of increasing responsibility in pharmaceuticals and biotechnology companies over the past 15 years, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, Anavex Life Sciences. He also co-founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences (Genesis Research) prior to founding Sellas.

Dr. Stergiou has held specific roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC).

Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including Central Nervous System, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA, EMEA and EU health authorities in addition to regulatory exposure in Australia and Japan.

Dr. Stergiou was part of the joint steering and oversight committee in the license deal of Paion’s desmoteplase drug with Forest Labs and part of senior management of Accentia Biopharmaceuticals and Biovest International. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology.

Dr. Stergiou holds a Doctor of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College and US American Institute of Medicine, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry.

Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals. He is a frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and lectured at post-secondary institutions including Columbia University, and numerous European universities.

He is fluent in English, German and Greek.


Aleksey N. Krylov , Interim Chief Financial Officer

Mr. Krylov has served as SELLAS’ Interim Chief Financial Officer since October 2017. Prior to joining SELLAS, Mr. Krylov acted as a consultant to CHR Capital Inc., where he functioned as a vice president and investment analyst with a focus on mergers and acquisitions, capital raising, private equity investment and restructuring transactions, among other items, from March 2012 through October 2017. Before that, Mr. Krylov provided consulting services to a number of additional companies through Ftera Advisors, LLC, or Ftera, a financial consulting firm that works with early-stage and small-cap companies in various industries including biotechnology. Mr. Krylov founded his consulting business in 2009, formed Ftera in 2012 and has been the managing director of Ftera since that time. Mr. Krylov began his career with SG Cowen’s equity capital markets group as an investment banking analyst. Mr. Krylov holds an M.B.A. from Columbia Business School and a B.S. in Business Administration from Babson College. He is a CFA charterholder.


Nicholas J. Sarlis, MD, PhD, FACP , Chief Medical Officer & Senior VP

Dr. Nicholas J. (Nick) Sarlis is the Chief Medical Officer and Senior VP of SELLAS Life Science Group, Ltd,, and an experienced clinician as well as recognized expert in the global pharmaceutical market with a focus in oncology and hematology.

As former Vice President and Head of Global Medical Affairs at Incyte Corporation, Dr. Sarlis led a global team supporting targeted and immuno-oncology pipeline agents. He led the integrated medical affairs plan to support the late clinical development of the innovative immuno-enhancer epacadostat , the original indoleamine 2,3-dioxygenase type-1 (IDO1) inhibitor. Dr. Sarlis and his team supported the successive launches of ruxolitinib (Jakafi®) – the original Janus kinase (JAK) inhibitor- in myelofibrosis and polycythemia vera. Prior to his time at Incyte, Dr. Sarlis held senior positions at Sanofi Aventis having led medical teams for launching key oncology and cancer supportive care products in both the United States and the European Union. He received his medical degree and doctorate from the University of Athens, and a Ph.D. in Molecular Biology/ Neuroendocrinology from the University of London. Dr. Sarlis is board certified by the American Board of Internal Medicine, and previously served as senior faculty at the National Institutes of Health and Associate Professor at MD Anderson Cancer Center.

Dr. Sarlis has published more than 130 articles (peer-reviewed papers, textbook chapters and monographs). He has received numerous awards, being most recently nominated as the recipient of the 2016 Annual Award by Cancer Research and Treatment Fund (CR&T). He is a Fellow of the American College of Physicians (FACP), the American College of Endocrinology (FACE), the Royal Society of Medicine (UK; FRSM), and the Molecular Medicine Society (FMMS).


Gregory M. Torre, PhD, JD , Chief Regulatory Officer and Senior Vice President, Technical Operations

Gregory M. Torre, PhD, JD, is a scientist-attorney with 37 years of hands-on international executive leadership experience in the pharmaceutical and biotech industries.

Prior to joining SELLAS, Dr. Torre served as Vice President, Worldwide Regulatory Strategy – Global Established Products at Pfizer, Inc. Prior to this, he was Vice President of Drug Development at Elusys Therapeutics Inc. Pharmaceutical Science and Legal Consultant at Axiom Law/The Torre Group. Previously, Dr. Torre held senior positions at Alvogen, including Vice President, Regulatory Affairs and Quality; Chief Compliance Officer, and Intellectual Property and Regulatory Council. Prior to joining Alvogen, Dr. Torre was the Senior Vice President for Regulatory Affairs, Quality and Technical Operations at NPS Pharmaceuticals. At Accentia, he was instrumental in developing FDA-acceptable surrogate markers and endpoints for an autologous vaccine to treat non-Hodgkin lymphoma. During his career, Dr. Torre also held leadership positions at Bristol-Myers Squibb, Sanofi, Sankyo and Sandoz/Novartis.

Dr. Torre received his J.D. from Brooklyn Law School, and he is a member of the Bar in the State of New Jersey, the District of Columbia and the United States Supreme Court. He received his BS in Pharmacy from St. John’s University, College of Pharmacy and Allied Health Professions and is a registered Pharmacist in the State of New York. He was also awarded an MS in Pharmacology/Toxicology and a PhD in Pharmacology/Toxicology from St. John’s University, College of Pharmacy.


Laura M. Katz, MPH , VP, Clinical Operations & Biostatistics

Laura M. Katz, MPH, is the Head of Clinical Operations & Biostatistics at SELLAS Life Sciences Group. Laura brings extensive experience in clinical development and clinical and statistical consulting in the pharmaceutical and biotechnology industries.

Prior to joining SELLAS, Laura served as Senior Clinical Project Manager/Senior International Manager at Novo Nordisk in the biopharmaceutical group, where held leading roles on global teams with responsibility for international management of clinical trials in Phases II to IV. Laura was also responsible for the oversight of clinical activities across multiple portfolios in pediatric and adult populations, and directed trials out of both the US and European offices. Previously, Laura served as Associate Director of Biostatistics and Clinical Project Management at Accentia Biopharmaceuticals and as a Consultant at Analytica International and Columbia University.

Laura holds a Master of Public Health in Epidemiology and Biostatistics from Columbia University and a Bachelor of Science in Biostatistics from Cornell University. She has published in prominent journals including the American Journal of Hematology; the American Journal of Public Health; the Journal of the American Academy of Child and Adolescent Psychiatry; and the Annals of Allergy, Asthma, and Immunology.


David Moser, JD , J.D. is V.P. of Legal Affairs at SELLAS Life Sciences Group, Ltd.

Mr. Moser has extensive experience in the biopharmaceutical industry spanning all fields of legal involvement. Prior to joining SELLAS, Mr. Moser served as Director of Legal Affairs and Secretary of BioVest International, Inc., a subsidiary of Accentia Biopharmaceuticals. He also has previously worked in brokerage, civil litigation and general corporate law.

Mr. Moser received a BA degree in Political Science & Economics from Columbia University, and a JD degree from Harvard Law School.

Scientific Advisory Board

David A.Scheinberg

David A.Scheinberg,MD, PHD

Jedd D. Wolchok

Jedd D. Wolchok,MD, PhD

Jeffrey Weber

Jeffrey Weber, MD, PHD


Alexander M.M. Eggermont, MD, PHD

Larry W. Kwak

Larry W. Kwak,MD, PHD

Javier Pinilla-Ibarz

Javier Pinilla-Ibarz, MD, PHD

Sattva Neelapu

Sattva Neelapu,MD, PHD

Guenther Koehne

Guenther Koehne,MD, PhD

David A. Scheinberg, MD, PhD, is Chair of the Center for Experimental Therapeutics and the Vincent Astor Chair at Memorial Sloan Kettering Cancer Center (MSKCC), where he treats patients with leukemia. Dr. Scheinberg also serves as Chair of the Molecular Pharmacology Program at the Sloan Kettering Institute. He is a professor of medicine and of pharmacology at Weill Cornell Medical College and a founder and director of the Therapeutics Discovery Institute, a joint effort of Weill Cornell, the Rockefeller University, and MSKCC.

Dr. Scheinberg’s research is focused on discovering and developing novel, specific immunotherapeutic agents and to understand their mechanisms of action as well as the mechanisms of resistance to them. Eight different therapeutic agents developed in Dr. Scheinberg’s laboratory have reached human clinical trials. His laboratory is also investigating cellular resistance mechanisms to these agents.

Dr. Scheinberg received his bachelor’s degree from Cornell University and his MD and PhD in pharmacology and experimental therapeutics from the Johns Hopkins University School of Medicine.

Jedd D. Wolchok, MD, PhD is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSKCC); an associate director of the Ludwig Center for Cancer Immunotherapy at MSKCC, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSKCC. He is director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. He is also the co-director of the Swim Across America laboratory at MSKCC, one of the foremost immunotherapy and melanoma research groups in the country.

His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. Most recently, Dr. Wolchok has initiated several clinical trials using plasmid DNA vaccines for patients with melanoma.

Dr. Wolchok has authored numerous articles concerning DNA vaccines, cytokine biology, and clinical care of melanoma and co-authored two chapters in the definitive textbook, Cutaneous Melanoma. Dr. Wolchok is also co-editor of the journal Cytotherapy.

Dr. Jeffrey Weber, a specialist in cancer immunotherapy, is currently deputy director of the Perlmutter Cancer Center and the co-director of the Melanoma Research Program at the New York University (NYU)-Langone Cancer Center. Dr. Weber is principal investigator on several ongoing studies funded by the National Cancer Institute (NCI) as well as industry, including trials in clinical drug development, vaccines, and studies on autoimmunity and melanoma. He earned his PhD in molecular biology from Rockefeller University (NY) in 1979 and his MD from New York University in 1980. Dr. Weber sat on the NCI’s Clinical Oncology Study section as well as the boards of the Melanoma Research Foundation and the Melanoma Therapeutics Foundation, and served as a chair of the Veterans Administration’s clinical oncology study section. He has published more than 150 articles in the top peer-reviewed journals in his field.

Alexander M.M. Eggermont is currently the Director General of Institut Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, as well as Professor of Oncology at the University Paris-Sud. He is the past Professor of Surgical Oncology and current Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam. He holds the honorary Chair of Surgical Oncology at the Catholic University of Louvain, Belgium. Prof. Eggermont is a past President of the European Cancer Organisation and European Organisation for Research and Treatment of Cancer (EORTC) and past Chair of the EORTC Melanoma Group. He is the current President of the European Academy of Cancer Sciences, the chairman of Cancer Core Europe and Chair of the International Jury for Comprehensive Cancer Centre Program in Germany, as well as board member of the European Society for Medical Oncology. He obtained his MD at the University of Amsterdam and PhD in tumor immunology at the Erasmus University in Rotterdam, both in the Netherlands, and was a Fellow of the NCI Surgery Branch in Bethesda, MD, USA. He has published more than 800 peer reviewed publications.

Larry W. Kwak, MD, PhD is Cancer Center Associate Director, Translational Research & Developmental Therapeutics for the City of Hope National Medical Center, Director of the Toni Stephenson Lymphoma Center within the Hematologic Malignancies and Stem Cell Transplantation Institute, and is endowed with the title of the Dr. Michael Friedman Professor in Translational Medicine. From 2004 to 2014, Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, where he also held the Jane and John Justin Distinguished Chair in Leukemia Research. Prior to his role at M.D. Anderson, Dr. Kwak served as Head of the Vaccine Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute for 12 years. His laboratory at the NCI was credited with the bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies. In 2010, Kwak was named to TIME Magazine’s TIME100 as one of the world’s 100 most influential people for his 20-year commitment to the science of cancer vaccines, specifically a personalized therapy for follicular lymphoma. Dr. Kwak received his medical degree from Northwestern University Medical School and earned his Ph.D. in tumor cell biology there in 1984. He also completed a residency in internal medicine and a fellowship in medical oncology at Stanford University Medical Center in California.

Dr. Javier Pinilla-Ibarz has a long track record of successfully applying immunology clinical and translational approaches to the treatment of leukemias and myelodysplastic syndromes. He is currently an associate member of the malignant hematology and immunology program and Director of Immunotherapy for Malignant Hematology at the H. Lee Moffitt Cancer Center, as well as an associate professor in the Department of Oncologic Sciences, University of South Florida College of Medicine, both in Tampa, FL. Dr. Pinilla-Ibarz received his MD and then PhD degrees from the University of Zaragoza, Spain. He then completed a research fellowship in Immunology at the Memorial Sloan-Kettering Cancer Center, as well as a Hematology and Oncology training at the same Institution. Dr. Pinilla-Ibarz has published more than 100 articles in the top peer-reviewed journals in his field.

Sattva Neelapu, MD, PhD, serves as an Associate Professor of Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas M.D. Anderson Cancer Center.

Dr. Neelapu laboratory is focused on characterization of immune-regulatory mechanisms in the tumor microenvironment in patients with lymphoma and development of novel therapeutic strategies for patients with lymphoma. His research is supported and recognized by numerous awards from national and international organizations including the National Institutes of Health, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, Doris Duke Charitable Foundation, and Leukemia and Lymphoma Society.

Dr. Neelapu obtained his medical degree in India and subsequently moved to the United States of America where he completed residency in Internal Medicine at Coney Island Hospital, Brooklyn, New York, and clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Guenther Koehne, MD, PhD is Chief of Bone Marrow Transplantation and Hematologic Oncology at the Miami Cancer Institute, part of Baptist Health South Florida. Prior to assuming this role in mid-2017, he was an Attending Physician of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center (MSKCC) and also held the position of Medical Director of the Cell Therapy Laboratory in the Bone Marrow Transplantation Laboratory at MSKCC since 2010. He was Associate Member and Assistant Attending Physician in the Allogeneic Bone Marrow Transplantation Service at MSKCC from 2007 to 2014.

He is Associate Professor of Medicine of the Weill Cornell Medical College of Cornell University. He leads research at the BMT Department/Immunology Program to develop adoptive immunotherapeutic strategies for post-transplant blood disorders. Dr. Koehne has particular expertise in the creation and monitoring of antigen-specific T cell responses in these patients. He is the Principal Investigator in active clinical trials using adoptive cell therapy following allogeneic stem cell transplants for multiple myeloma and plasma cell leukemia patients.

Dr. Koehne graduated with his Medical Degree in 1991 from the Medical University of Hamburg in Germany, and received his PhD from the same institution in 1996. He completed residencies at the Medical University of Hamburg General Hospital and Rush University Medical Center, before undertaking his fellowship training at MSKCC and Weill Cornell Medical College. He has been at MSKCC since 1996. Dr. Koehne is board certified in both Internal Medicine and Medical Oncology, and keeps up to date with the latest advances in his field by maintaining a professional membership with the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation.